Biotech

Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2012 Conference Call

CARY, NC: ...

Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency

DEERFIELD, IL: ...

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments

CAMBRIDGE, MA: Upcoming Meetings With FDA Will Determine Fastest Path to Pursue Eteplirsen Approval; Additional Drugs for Duchenne Muscular Dystrophy (DMD) Continue to Progress Through Preclinical Development; 2013 ...

Prana's PBT434 Inhibits Accumulation of Parkinson's Protein and Subsequent Death of Brain Cells.

MELBOURNE, AUSTRALIA: New Data to Be Presented at the 11th International Conference on Alzheimer's and Parkinson's Disease and the 11th International Basal Ganglia Society Meeting in Eilat, Israel ...

SymBio Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

TOKYO: ...

Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

TUSTIN, CA: ...

ProMetic Reduces Short-Term Liabilities

LAVAL, QUEBEC: ...

Lorus Therapeutics Announces Allowance of Chinese Patent for Anticancer Drug LOR-253

TORONTO, ONTARIO: ...

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results

PALATINE, IL: ...

Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

MELBOURNE, AUSTRALIA: New Data to Be Presented at the 11th International Conference on Alzheimer's and Parkinson's Disease ...